罗格列酮对非糖尿病代谢综合征患者糖脂代谢、胰岛素抵抗及炎症指标的影响

157名伴有低HDL-C和代谢综合征（MS）的非糖尿病患者随机分为两组，分别给予马来酸罗格列酮4mg或8mg／d治疗12周之后，两组FPG、2hPG、HbA1C、Fins、HOMA—IR、TG、hsC—RP、纤维蛋白原（FIB）和WBC均下降，HDL-C升高（P均＜0．05），8mg组变化尤著；两组TC和LDL-C均无明显变化（P〉0．05）。对伴有低HDL—C和MS的非糖尿病患者予罗格列酮治疗能有效改善血糖和血脂，减轻IR和炎症状态。

Effects of rosiglitazone on glucose and lipid metabolism, insulin resistance and inflammatory markers in nondiabetic patients with metabolic syndrome

Objective To evaluate the effects of rosiglitazone therapy on plasma glucose and lipids, insulin resistance and serum inflammatory factors in nondiabetic patients with metabolic syndrome（MS）. Methods 157 nondiabetic patients with low HDL-C and MS were randomly allocated into two groups： rosiglitazone 4mg or 8mg daily for 12 weeks. The lipids profile, HOMA- IR, hsC-RP, FIB and peripheral white blood cell counts （WBC） were assayed before and after treatment. Results After treatment, FPG, 2hPG, HbA1c, Fins, HOMA-IR, TG, hsC-RP, FIB and WBC were decreased in both groups, and HDL-C was increased（P〈0. 05）. These parameters changed to a greater extent in 8mg/d vs 4mg/d treatment group. The levels of TC and LDL-C did not significantly change after treatment（P〉0.05）. Conclusions In nondiabetic patients with low HDL- C and MS, rosiglitazone improves plasma glucose and lipids, and lessens insulin resistance and inflammatory state.